EP1096927A1 - Composition for treatment of stress - Google Patents
Composition for treatment of stressInfo
- Publication number
- EP1096927A1 EP1096927A1 EP99934107A EP99934107A EP1096927A1 EP 1096927 A1 EP1096927 A1 EP 1096927A1 EP 99934107 A EP99934107 A EP 99934107A EP 99934107 A EP99934107 A EP 99934107A EP 1096927 A1 EP1096927 A1 EP 1096927A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- day
- administered
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the invention relates to a novel process for treating stress in a subject suffering from at least one symptom of stress. More specifically, the invention relates to the use of drugs which enhance serotonin-mediated neurotransmission such as fenfluramines for treating stress in such a subject.
- a patient suffering from a stress related disorder may exhibit a variety of types of symptoms. These symptoms can include anxiety, depression, and overeating.
- the conventional treatment for a patient suffering from a stress related disorder is by use of drugs such as the benzodiazepines or by use of beta- blocking drugs such as propranolol.
- Disclosed here is a novel treatment method for stress in a patient, which method uses drugs hitherto unknown as useful for treating stress.
- the novel method disclosed herein provides a useful method for treating patients suffering from stress and exhibiting at least one symptom thereof. In a specific embodiment of the invention, said method has been found particularly useful for treating the stress felt by subjects who also suffer from overeating disorders or who overeat in reaction to the stress that they are experiencing.
- a number of compounds are known to stimulate or enhance serotonin-mediated neurotransmission and are sometimes referred to as serotoninergic drugs. These compounds include the following: d,l-fenfiurarnine, dexfenfluramine, tryptophan, lithium, chlorimipramine, cyanimipramine, fluoxetine, paroxetine, fluvoxamine, citalopram, femoxitine, cianopramine, sertraline, sibutramine, venlafaxine, ORG 6582, RU 25591, LM 5008, DU 24565, indalpine, CGP 6085/A, W ⁇ 25093, alaprociate, zimelidine, trazodone, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, nortriptyline, dibenzoxazepine, deprenyl, isocarboxazide, phenelzine, tranylcypromine,
- Suitable salts can be formed from the above compounds, for example, as addition salts using the following acids: the hydrohalic acids, sulfuric acid, phosphoric acid or an organic acid such as acetic acid, maleic acid, valeric acid, caproic acid, benzoic acid or nicotine acid.
- fenfluramines here is meant a racemic mixture of d,l-fenfluramine, which is also called N-ethyl- ⁇ -methyl-3-(trifluoro-methyl)benzeneethanamine; the dextrorotatory isomer known as dexfenflurarnine and also as d-fenfluramine; or the pharmaceutically acceptable salts of these compounds.
- Suitable salts can be formed from dexfenflurarnine or d,l-fenfluramine, for example, as addition salts using the following acids: the hydrohalic acids, sulfuric acid, phosphoric acid or an organic acid such as acetic acid, maleic acid, valeric acid, caproic acid, benzoic acid or nicotinic acid.
- the active serotonin-mediated neurotransmission stimulating compound may be administered to a patient as a pharmaceutical composition comprising the active compound admixed with a pharmaceutically acceptable carrier, including one or more excipients.
- fenfluramines may be administered to a patient as a pharmaceutical composition comprising either dexfenflurarnine or d,l-fenfluramine admixed with a pharmaceutically acceptable carrier, including one or more excipients.
- the terms “subject” and “patient” may be used interchangeably to refer to a human exhibiting at least one symptom of stress.
- compositions of this invention are suitable for parenteral, buccal, sublingual or rectal administration.
- the resulting pharmaceutical compositions are, for example, tablets, coated tablets, capsules, soft gelatin capsules, drinkable emulsions, suspensions or solutions for oral or injectable administration, sublingual tablets or suppositories. They may also be formulated into a sustained release form.
- excipients which may be used for these purposes include talc, magnesium phosphate, lactose or silica or the like.
- compositions of this invention may also be flavored, colored or coated with a wax or a plasticizer. It is to be understood that those skilled in the art of pharmaceutical formulation will be able to make a variety of formulations that would be within the scope of this disclosure and the appended claims, without departing from the spirit and teachings of the invention. It is intended that all such formulations be included in this invention.
- the invention may be practiced by administering serotonin-mediated neurotransmission stimulating compounds, for example, fenfluramines, to a subject as a single unit dose one or more times per day, or as a plurality of unit doses once or more times per day without deviating from the teachings of the invention.
- serotonin-mediated neurotransmission stimulating compounds for example, fenfluramines
- halogenated amphetamines may also be useful to treat stress in a subject who is suffering from the kind of stress alleviated by the fenfluramine treatments of the present invention.
- Such other useful drugs may include specific drugs that are not halogenated amphetamines including, but not limited to, effexor, nefazodone, bupropion, paroxetine, fluoxetine, and sertralin.
- Dexfenflurarnine and d,l-fenfluramine are known anorectic agents as disclosed in U.S. Patent No. 3,198,834.
- serotoninergic drugs in general nor dexfenflurarnine nor d,l-fenfluramine has been known to be effective as a treatment for stress in a patient.
- Fenfluramines are known to be effective drugs for treating obesity.
- the racemic mixture, d,l- fenflurarnine was disclosed in U.S. Patent 4,452,815, granted to Wurtman and Wurtman, as being effective for inhibiting the abnormal craving for carbohydrates which afflicts some people and which is associated with their obesity.
- Dexfenflurarnine is also indicated for use in treating patients who cannot control their eating habits or appetite.
- the use of dexfenflurarnine for this purpose was disclosed in U.S. Patent 4,309,445. In both of these patents the use proposed for fenfluramines was for treating a patient's appetite or craving for certain types of food.
- Fenfluramines are serotoninergic drugs that inhibit the abnormal craving for high carbohydrate foods, which leads to a positive caloric balance and subsequent obesity in certain people. Some, but not all, people benefit from the administration of dexfenfluramine by having their craving for certain foods inhibited.
- This above cited publication does not disclose or teach any use of dexfenfluramine or d,l-fenfluramines for treating stress itself in obese patients, or make any suggestion that these fenfluramines may be effective as a treatment for stress itself.
- the publication describes the serotoninergic fenfluramines as acting to facilitate weight loss in subjects in three ways: "They accelerate the onset of satiety and enhance basal metabolic rate by about 100 calories per day.
- dexfenflurarnine for treating animals inflicted with periodic pain is discussed in Dexfenfluramine: Effects on Food Intake in Various Animal Models, Neil E. Rowland and Janis
- This article discloses the administration of dexfenfluramine to rats exhibiting increased eating behavior in response to tail pinching.
- the tails of the rats were pinched as part of an experimental protocol, which was found to cause the rats to eat larger amounts of food than rats whose tails were not pinched.
- Dexfenfluramine (DF) was found to decrease the eating behavior of the tail pinched rats.
- Dexfenfluramine was known prior to the Rowland et al. article to depress eating activity, however, as shown in Wurtman et al., Science, vol. 198, pp. 1178-1180, December, 1977 incorporated by reference. The authors discussed the implications of their experiments with regard to stress-induced eating as follows on page S37 (DF indicating dexfenfluramine):
- DF Mild tail pressure induces eating and gnawing in rats, and this may be a model of stress- induced eating in humans.
- Garattini reported that DF potently inhibits tail pressure-induced eating, and that the DI 50 of 0.6 mg/kg is about one-half of the doses effective in the other paradigms reviewed so far. It was previously reported that racemic fenfluramine inhibits tail pressure-induced eating as well as concurrent behaviors such as gnawing, locomotion, and vocalization. In the study with DF, only the amount eaten was reported, rather than all oral behaviors. These data thus suggest that DF may be an especially potent inhibitor of stress- related eating. Further studies are needed to clarify the effect of DF on other oral behaviors, as well as whether it has 'antistress' effects along with its anorectic action.”
- dexfenfluramine inhibits eating in tail pinched rats. It was not previously known that serotoninergic drugs, for example dexfenfluramine or d,l-fenfluramine could be an effective treatment for stress.
- serotoninergic drugs for example dexfenfluramine or d,l-fenfluramine could be an effective treatment for stress.
- the authors of this article indicated only that fenfluramines inhibit tail pinching-induced eating and other behaviors stemming from the tail pinching protocol. They did not disclose that the fenfluramines could be used as treatments for reducing stress itself. Thus, Rowland et al. had no idea dexfenfluramine would exhibit any stress relieving activity per se. Indeed, it is doubtful that tail pinching and the consequent behavior from the rat induced by the tail pinching could serve as a meaningful, let alone reliable, model for the types of stress experienced by humans.
- the present invention is a novel treatment for stress and symptoms of stress in a subject.
- the applicants have discovered that administering Page 7, line 18.
- Administering serotoninergic drugs in general and fenfluramines in particular to a patient can bring about a reduction in the stress felt by patient and the symptoms of stress manifested by the patient.
- the treatment of stress and stress related symptoms of a patient with these compounds has not been reported previously.
- the present invention provides an appropriate treatment for stress in human patients, especially those suffering from stress-induced overeating.
- This invention is based on the discovery that the serotoninergic drugs, for example fenfluramines, such as d,l-fenfluramine, dexfenfluramine, or their salts can alleviate symptoms of stress in patients, when administered in effective amounts or at appropriate dosages.
- fenfluramines such as d,l-fenfluramine, dexfenfluramine, or their salts
- the present invention is directed to a method of treating a human subject exhibiting one or more symptoms of stress, which comprises administering to the subject an effective amount of a compound which enhances serotonin-mediated neurotransmission such as d,l- fenfluramine or dexfenfluramine, or a pharmaceutically acceptable salt thereof.
- a compound which enhances serotonin-mediated neurotransmission such as d,l- fenfluramine or dexfenfluramine, or a pharmaceutically acceptable salt thereof.
- an effective dose ranges from about 15 to about 150 mg/day, preferably from about 40 to about 80 mg/day.
- an effective dose ranges from about 5 to about 150 mg/day, preferably from about 15 to about 45 mg day.
- a treatment is provided which results in a reduction in the stress level of the patient experiencing emotional and other kinds of stress. Accordingly, it is an object of the invention to provide a treatment for stress perceived by a stress-induced overeating patient.
- the method comprises the administration of stimulators of serotonin-mediated neurotransmission such as fenfluramines to a patient with stress related symptoms.
- the method comprises the administration of effective amounts of either d,l-fenflurarnine, dexfenfluramine, or their salts.
- Other preferred embodiments provide detailed disclosure of the use of other compounds which enhance serotonin-mediated neurotransmission.
- a number of compounds are shown to enhance serotonin-mediated neurotransmission, and thus to be useful in treating humans with one or more symptoms of stress.
- These compounds include the following: d,l-fenfluramine, dexfenfluramine, tryptophan, lithium, chlorimipramine, cyanimipramine, fluoxetine, paroxetine, fluvoxamine, citalopram, femoxitine, cianopramine, sertraline, sibutramine, venlafaxine, ORG 6582, RU 25591, LM 5008, DU 24565, indalpine, CGP 6085/A, WY 25093, alaprociate, zimelidine, trazodone, amitriptyline, imipramine, trimipramine, doxepin, protriptyline, nortriptyline, dibenzoxazepine, deprenyl, isocarboxazide, phenelzine, tranylcypromine,
- 6-Chloro-2-(l-piperazinyl)pyrazine (MK-212), is obtained from Merck & Co., Inc. Whitehouse Station, N J.
- (S)-2-(4, 4, 7-trimethyl- 1 , 4-dihydro-indeno ( 1 , 2-B) pyrrol- 1 -yl- 1 - methylethylamine (Ro 60-175/ORG 35030) is obtained from F. Hoffmann-LaRoche Ltd., Basel, Switzerland.
- (S)-2-(Chloro-5-fluoro-indol-l-yl)-l -methylethylamine (Ro 60-0332/ORG 35035) is obtained from F.
- l-(2,5-dimethoxy-4-iodophenyl)-2- aminopropane DOI
- m-CPP l-(3- Chlorophenyl)piperazine
- the present invention as disclosed herein, also includes a method of making a medicament for treating stress, wherein the method comprises a step of mixing dexfenfluramine or d,l-fenfluramine with a pharmaceutically acceptable inert ingredient.
- a subgroup of obese individuals is identified, which individuals describe themselves as being unable to control their eating and who attempt to continue on a weight-reducing diet when experiencing emotional distress. These patients are treated for four months by enrolling them in a weight loss program that includes the administration of dexfenfluramine at 30 mg/day and which involves adherence to a reduced-calorie meal plan. The use of dexfenfluramine is found to enhance the ability of stressed overeaters to lose weight.
- Body Mass Index is defined as the weight in kilograms of a subject, divided by the subject's height in meters squared. Applicants conduct a survey of 189 female women of normal body weight (Body Mass Index
- CES-D Center for Environmental Studies Depression Form
- the obese, stressed patients receiving dexfenfluramine exhibit a weight loss of 12 ⁇ 1.8 pounds (5.45 ⁇ 0.82 kg) during the four month study period.
- the mean group score which at the beginning of the study is 9.4, fluctuates between 7 and 8 through the treatment period. Scores on the appetite and stress-induced overeating scales are also reduced compared with baseline levels. The initial score on the appetite and hunger scale is 10.5, which decreases to 5.0 during the treatment period.
- the summed Tension, Depression, Anger and Confusion scores on the POMS test at baseline is 24. This number drops to 16.8 during the study period. Moreover, the score on the emotional triggers to overeating report drops from 23.4 ⁇ 9.8 to 8.6 ⁇ 8.5 standard deviations by the end of the treatment period.
- treatment with a fenfluramine, dexfenfluramine specifically promotes the ability to control food intake and to lose weight among the stress-induced overeaters. More surprisingly, treatment reduces the indicators of stress in these patients.
- Example 1 involves treatment with d,l-fenfluramine at 30 mg/day.
- a preferred dosage is about 5 mg/day to about 150 mg/day.
- C.B. is a 48 year old white single female. She states in her screening forms that when she is upset or stressed she snacks on chocolate, popcorn, crackers, pretzels, and candy. She notes that she overeats when feeling frustrated, overwhelmed, and lonely and writes in answer to a question about whether she has difficulty in sticking to a diet when upset or stressed: "In the past when I am not in a formalized program, somehow my brain thinks I'm given a license to graze to placate my emotions when stressed. I tend to break all my own 'house' rules and eat anything I want.”
- Her starting weight is 216 pounds (98.2 kg) and after 4 months on dexfenfluramine, drops to 205.5 pounds (93.4 kg).
- Her baseline CES-D Mood Scores drop from 5 to 1 over the treatment period, and her emotional triggers decrease from a baseline of 23 to a value of 4 after four months. Hence, the treatment also greatly relieves her emotional distress.
- Example 2 involves treatment with dexfenfluramine hydrochloride at 30 mg/day.
- a preferred dosage range is from about 15 mg/day to about 45 mg/day.
- CM. is a 46 year old white married physician and mother of two. She reports in her initial screening report that when stressed, she snacks on chocolate, candy, chips, cookies, cake/pie, and popcorn. She writes: "I was on Weight Watchers, doing well even during vacation. But upon the start of the school year with all the schedules to handle, I was unable to keep with the program. Then the Christmas holidays were upon us and I was working really hard at the office. I started gaining weight and I could not stop eating. My appetite has tripled and it is hard for me to say no.”
- Example 3 involves the treatment of a 57 year old married female with lithium carbonate at 900 mg/day for four months.
- a preferred dose is about 600 mg/day to about 1500 mg/day.
- D.R. states in her screening forms that when she is upset or stressed she overeats on beer and crabs, as well as snack food such as potato chips and peanuts. This occurs when she feels stress or frustration from her employment as a government lawyer.
- Her starting weight is 246 pounds (111.8 kg) and after 4 months on lithium drops to 225 pounds (102.3 kg).
- Her baseline CES-D Mood Scores drop from 4 to 2 over the treatment period, and her emotional triggers decrease from a baseline of 15 to a value of 7 after four months. Hence, the treatment also greatly relieves her emotional distress and stress.
- Example 4 involves the treatment of a 35 year old single white female with fluoxetine hydrochloride at a dose from 20 mg/day for the first two weeks, 40 mg/day the second two weeks, 60 mg/day the third two weeks, and 80 mg/day through the end of the four month trial.
- the preferred dose is about 10 mg/day to about 160 mg/day.
- Example 5 involves the treatment of a 76 year old single white female with fluvoxamine maleate at a dose from 50 mg/day for the first week, 100 mg/day the second week, and 150 mg/day through the end of the four month trial.
- the preferred dose is about 25 mg/day to about 300 mg/day.
- J.B. complains of feelings of stress associated with social activities in the retirement community in which she lives. While clearly overweight, she does not complain about weight nor apparently recognizes her condition.
- Her starting weight is 302 pounds (137.3 kg) and after 4 months on dexfenfluramine, drops to 286 pounds (130 kg).
- Her baseline CES-D Mood Scores drop from 23 to 17 over the treatment period, and her emotional triggers decrease from a baseline of 34 to a value of 24 after four months. The treatment relieves her social stress and has the additional benefit of modest weight reduction.
- Example 6 involves the treatment of a 42 year old married white female with sertraline hydrochloride at a dose from 50 mg/day for the first week, 100 mg/day the second week, and 200 mg/day through the end of the four month trial.
- the preferred dose is about 25 mg/day to about 400 mg/day.
- P.Q. is employed as an accountant, has two small children, and experiences stress during the tax season. She eats between meals and reports wakening at night with anxiety which is relieved by consumption of ice cream.
- Example 7 involves the treatment of a 38 year old single white female with venlafaxine hydrochloride at a dose from 75 mg/day for the first week, 100 mg/day the second week, and 150 mg/day through the end of the four month trial.
- the preferred dose is about 50 mg/day to about 300 mg/day.
- Example 8 involves the treatment of a 44 year old single white female with amitriptyline hydrochloride at a dose from 75 mg/day for the first week, to 100 mg/day through the end of the four month trial.
- the preferred dose is about 50 mg/day to about 200 mg/day.
- E.E. reports stress from her employment as a dispatcher for a trucking company. Her discomfort is relieved by eating fried foods, especially fried potatoes.
- Her starting weight is pounds (90.0 kg) and at the end of 4 months on dexfenfluramine, her weight drops to pounds (82.6 kg).
- Her baseline CES-D Mood Scores drop from 29 to 18 over the treatment period, and her emotional triggers decrease from a baseline of 25 to a value of 3 after four months. Hence, the treatment also greatly relieves this patient's stress levels.
- Example 9 involves the treatment of a 30 year old married white female with trazodone hydrochloride at a dose of 100 mg/day in divided doses of 50 mg each through the end of the four month trial.
- the preferred dose is about 50 mg/day to about 200 mg/day.
- Her starting weight is 203 pounds (92.3 kg) and at the end of 4 months on sertraline, her weight drops to 160 pounds (72.7 kg).
- Her baseline CES-D Mood Scores drop from 9 to 1 over the treatment period, and her emotional triggers decrease from a baseline of 12 to a value of 3 after four months. Hence, the treatment relieves both the stress levels and the overweight.
- Example 10 involves the treatment of a 31 year old married white female with imipramine hydrochloride at an intramuscular dose of 75 mg/day through the end of the four month trial.
- the preferred dose is about 50 mg/day to about 150 mg/day.
- A.R. is employed at a consulting engineering firm and attends law school at night. Her regimented schedule and lack of exercise may contribute to her feelings of stress, which engenders over-eating.
- her emotional triggers decrease from a baseline of 22 to a value of 8 after four months.
- the treatment also greatly relieves her emotional distress.
- Example 11 involves the treatment of a married 42 year old white female with trimipramine maleate at a dose from 75 mg/day for the first week, to 100 mg/day through the end of the four month trial.
- the preferred dose is about 50 mg/day to about 200 mg/day.
- A.B. a teacher in a metropolitan school, reports stress which she attributes to her work and generally unhappy home life. She is unable to control episodic binge eating of ice cream and cake.
- Her starting weight is 180 pounds (81.8 kg) and at the end of 4 months on trimipramine, her weight drops to 158 pounds (71.8 kg).
- Her baseline CES-D Mood Scores drop from 25 to 13 over the treatment period, and her emotional triggers decrease from a baseline of 14 to a value of 3 after four months. Hence, the treatment also greatly relieves this patient's stress levels.
- Example 12 involves the treatment of a single 50 year old white female with phenelzine sulfate at a dose from 45 mg/day for the first week, to 60 mg/day through the end of the four month trial, each daily dose taken in three portions.
- the preferred dose is about 15 mg/day to about 120 mg/day.
- D.C. is a suburban bus driver and finds driving in traffic stressful. She constantly diets but is unable to successfully lose weight.
- Her starting weight is 184 pounds (83.6 kg) and at the end of 4 months on phenelzine, her weight drops to 174 pounds (79.1 kg).
- EXAMPLE 13 The effect of the hydrochloride salt of 6-Chloro-2-(l-piperazinyl)pyrazine (MK-212, which is obtained from Merck & Co., Inc. Whitehouse Station, NJ, on stress related eating in animals is determined through the observation of the effect of experimental compounds on stress-related eating in adult Sprague-Dawley rats. These rats are widely used as a recognized animal model useful in predicting the effect of serotoninergic drugs in humans.
- MK-212 6-Chloro-2-(l-piperazinyl)pyrazine
- the results are shown in Table 13.
- the average amount of food in mg which is consumed per rat 8 hours after initiation of the trials is shown in the following table.
- the relative amounts of stress eating with the amount at 0 mg/kg MK-212 as 100% is also shown in the Stress Eating row.
- the preferred daily dose of MK-212 is about 1 mg/kg body weight to about 10 mg/kg body weight.
- Table 13 shows MK-212 reduces stress-related eating which indicates MK-212 reduces stress.
- Example 14 shows the effect of (S)-2-(4, 4, 7-trimethyl-l, 4-dihydro-indol (1, 2-B) pyrrol- 1- yl-1 -methylethylamine (Ro 60-175/ORG 35030) which is obtained from F. Hoffmann-LaRoche Ltd., Basel, Switzerland, on stress-induced eating.
- the experiment is done as in Example 13 and Table 13 except that Ro 60-175/ORG 35030 is used instead of MK-212.
- the preferred daily dose of Ro 60- 175/ORG 35030 is about 1 mg/kg body weight to about 10 mg/kg body weight.
- Table 14 shows that Ro 60-175/ORG 35030 reduces stress related eating which indicates Ro 60-175/ORG 35030 reduces stress.
- Ro 60-0332/ORG 35035 The effect of (S)-2-(Chloro-5-fluoro-indol-l-yl)-l -methylethylamine (Ro 60-0332/ORG 35035) which is obtained from F. Hoffmann LaRoche Ltd., Basel, Switzerland, on eating in stressed rats is determined as in EXAMPLE 13 and Table 13, except Ro 60-0332/ORG 35035 is used rather than MK-212.
- the preferred daily dose of Ro 60-0332/ORG 35035 is about 1 mg/kg body weight to about 10 mg/kg body weight.
- Table 15 shows that Ro 60-0332/ORG 35035 reduces stress-related eating which indicates Ro 60-0332/ORG 35035 reduces stress.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9301398P | 1998-07-16 | 1998-07-16 | |
US93013P | 1998-07-16 | ||
PCT/US1999/016153 WO2000003701A1 (en) | 1998-07-16 | 1999-07-16 | Composition for treatment of stress |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1096927A1 true EP1096927A1 (en) | 2001-05-09 |
EP1096927A4 EP1096927A4 (en) | 2002-09-04 |
Family
ID=22236330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99934107A Withdrawn EP1096927A4 (en) | 1998-07-16 | 1999-07-16 | STRESS TREATMENT COMPOSITION |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1096927A4 (en) |
JP (1) | JP2002520353A (en) |
CA (1) | CA2337507A1 (en) |
WO (1) | WO2000003701A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR021155A1 (en) | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | TREATMENT OF NEUROTIC DISORDERS |
WO2003082286A1 (en) * | 2002-04-03 | 2003-10-09 | Chemon Inc. | Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same |
WO2003090743A1 (en) * | 2002-04-24 | 2003-11-06 | Cypress Bioscience, Inc. | Prevention and treatment of functional somatic disorders, including stress-related disorders |
RU2617512C1 (en) | 2015-10-23 | 2017-04-25 | Общество с ограниченной ответственностью "Нормофарм" | Means with antistress, anxiolytic and antidepressant activity and composition based thereon |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
US20230023092A1 (en) | 2019-04-17 | 2023-01-26 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1593659A1 (en) * | 1983-12-29 | 1990-09-23 | Московская ветеринарная академия им.К.И.Скрябина | Method of preventing stress of chickens |
JPH06699B2 (en) * | 1984-08-11 | 1994-01-05 | カネボウ食品株式会社 | Mental stability chewing gum |
HU202108B (en) * | 1986-07-30 | 1991-02-28 | Sandoz Ag | Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol |
US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
AU676672B2 (en) * | 1992-02-21 | 1997-03-20 | Novartis Ag | Brofaromine as an agent for treating post-traumatic stress |
ES2304041T3 (en) * | 1993-06-28 | 2008-09-01 | Wyeth | NEW TREATMENTS THAT USE FENETILAMINE DERIVATIVES. |
FR2710916B1 (en) * | 1993-10-04 | 1995-12-22 | Pasteur Institut | Compounds of a peptide nature having a modulating activity of the serotonergic response; diagnostic and therapeutic applications. |
TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
US5597826A (en) * | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
US5502080A (en) * | 1994-11-01 | 1996-03-26 | Hitzig; Pietr | Combined use of dopamine and serotonin agonists in the treatment of allergic disorders |
JPH0940648A (en) * | 1995-08-02 | 1997-02-10 | Yamanouchi Pharmaceut Co Ltd | New 8-(2-aminoalkoxy)quinoline derivative |
US5852020A (en) * | 1996-11-22 | 1998-12-22 | Bristol-Myers Squibb Company | Nefazodone: use in treating post traumatic stress disorder |
-
1999
- 1999-07-16 CA CA002337507A patent/CA2337507A1/en not_active Abandoned
- 1999-07-16 JP JP2000559836A patent/JP2002520353A/en active Pending
- 1999-07-16 EP EP99934107A patent/EP1096927A4/en not_active Withdrawn
- 1999-07-16 WO PCT/US1999/016153 patent/WO2000003701A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1096927A4 (en) | 2002-09-04 |
CA2337507A1 (en) | 2000-01-27 |
JP2002520353A (en) | 2002-07-09 |
WO2000003701A1 (en) | 2000-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6579899B1 (en) | Composition for treatment of stress | |
Blackwell | Adverse effects of antidepressant drugs: part 1: monoamine oxidase inhibitors and tricyclics | |
Collins et al. | Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11. 3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes | |
Silverstone et al. | Serotoninergic mechanisms in human feeding: the pharmacological evidence | |
Trenchard et al. | Naloxone reduces the food intake of normal human volunteers | |
Goodwin et al. | A psychobiological approach to affective illness | |
US20040101575A1 (en) | Comprehensive pharmacologic therapy for treatment of obesity | |
US5804592A (en) | Method for improving disturbed behavior and elevating mood in humans | |
EP0053175B1 (en) | Use of d-fenfluramine for the manufacture of a medicament for modifying feeding behavior | |
US7268161B2 (en) | Comprehensive pharmacologic therapy for treatment of obesity including cysteine | |
JP2022514510A (en) | How to treat depression | |
US20090012177A1 (en) | Treatment of psychiatric disorders using entacapone, tolcapone and other COMT inhibitor or MB-COMT inhibitor drugs | |
Finer | Present and future pharmacological approaches | |
EP1096927A1 (en) | Composition for treatment of stress | |
Vivero et al. | A close look at fenfluramine and dexfenfluramine | |
Burd et al. | Anticonvulsant medications: an latrogenic cause of tic disorders | |
US20090281112A1 (en) | Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders | |
Rubino et al. | A review of topiramate and phentermine: a combined therapeutic approach for obesity | |
Moorhouse et al. | Carbohydrate Craving by Alcohol‐Dependent Men During Sobriety: Relationship to Nutrition and Serotonergic Function | |
Trygstad | Drugs in the treatment of bulimia nervosa | |
US20240197704A1 (en) | Treatment methods and compositions comprising perampanel | |
AU743788B2 (en) | Method of improving disturbed behavior and elevating mood in humans | |
Tablets et al. | PrTEVA-BUPROPION XL | |
WO2020158415A1 (en) | Composition for competitive inhibition of orexin receptors | |
WO2025099490A2 (en) | Compositions and treatments for fragile x syndrome and autism spectrum disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010215 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 45/08 A, 7A 61K 31/55 B, 7A 61P 9/12 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020718 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040202 |